Dr. Anne M. Hatch, DO
Neurology (Neurology Physician)
5090 N 40th St Ste 250a
Phoenix, AZ 85018
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 299
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 007965 · AZ license R2436
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
- Honorhealth Scottsdale Shea Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Osborn Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Thompson Peak Med Ctr Scottsdale, AZ
- Honorhealth Deer Valley Medical Center Phoenix, AZ
Medical groups
- Honorhealth Ambulatory (630 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 299
- Services billed
- 21,433
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 14,400 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 90 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 75 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 73 | 53 |
| Established patient office or other outpatient visit, 20-29 minutes | 57 | 50 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 27 | 12 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 27 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 10-19 minutes | 21 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Phoenix, AZ | 205 |
| Pregabalin Other prescribers in Phoenix, AZ | 147 |
| Lamotrigine Other prescribers in Phoenix, AZ | 105 |
| Baclofen Other prescribers in Phoenix, AZ | 100 |
| Tramadol Hcl Other prescribers in Phoenix, AZ | 82 |
| Pyridostigmine Bromide Other prescribers in Phoenix, AZ | 71 |
| Duloxetine Hcl Other prescribers in Phoenix, AZ | 68 |
| Riluzole | 54 |
| Topiramate Other prescribers in Phoenix, AZ | 51 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 51 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $392 in total to this clinician.
| Janssen Biotech, Inc. | $214 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.40 |
| Food and Beverage | $308 |
|---|---|
| Education | $83.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 16, 2025 | Education in-kind | $83.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $222,426 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension …
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Novartis Pharmaceuticals Corporation - A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
Ipsen Pharma Sas · Completed · NCT04936542
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.